EP Patent
EP1443919A4 — Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
Assigned to Bristol Myers Squibb Co · Expires 2006-03-22 · 20y expired
What this patent protects
Patent listed against Brenzavvy.
Drugs covered by this patent
- Brenzavvy (BEXAGLIFLOZIN) · Theracosbio
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.